Phase 2 Leukaemia Trial, Recruiting (NCT06058572)

Phase 2 Leukaemia Trial, Recruiting NCT06058572 Sponsor: Tata Memorial Centre Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06058572 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are an adult diagnosed with acute leukemia and are scheduled to receive a stem cell transplant from a donor (called an allogeneic transplant)
You are generally able to carry out daily activities, with little or no limitation caused by your illness (confirm with trial site)
Your liver is working well enough, as shown by recent blood tests (confirm with trial site)

Who may not be able to join:

You have had an allergic reaction to a medicine called rifaximin, or to similar antibiotics in the same family (such as rifampicin)
You have been diagnosed with, or have a history of, inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)
You have had a large portion of your bowel surgically removed in the past, or you currently have a colostomy (a surgical opening in the abdomen to collect waste)
You are currently taking any of the following medicines: verapamil (often used for heart conditions), ketoconazole, or itraconazole (both antifungal medicines)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06058572

Sponsor: Tata Memorial Centre

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

More information: https://clinicaltrials.gov/study/NCT06058572

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are an adult diagnosed with acute leukemia and are scheduled to receive a stem cell transplant from a donor (called an allogeneic transplant)
You are generally able to carry out daily activities, with little or no limitation caused by your illness (confirm with trial site)
Your liver is working well enough, as shown by recent blood tests (confirm with trial site)

Who may not be able to join:

You have had an allergic reaction to a medicine called rifaximin, or to similar antibiotics in the same family (such as rifampicin)
You have been diagnosed with, or have a history of, inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)
You have had a large portion of your bowel surgically removed in the past, or you currently have a colostomy (a surgical opening in the abdomen to collect waste)
You are currently taking any of the following medicines: verapamil (often used for heart conditions), ketoconazole, or itraconazole (both antifungal medicines)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Tata Memorial Centre

Registry

ClinicalTrials.gov

Start date

2 August 2024

Est. completion

2 August 2027

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Impact of rifaximin on gut microbial diversity.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov